Athena Pharmaceutiques Oral Dispersible Tablets

Athena Pharmaceutiques Oral Dispersible Tablets

X

Find Clinical Drug Pipeline Developments & Deals by Yuyu Pharma

Yuyu Pharma
Developments
Full Screen View

Yuyu Pharma

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

2 News

2 News

DEVELOPMENTS

3 Drug(s) in Development

3 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Yuyu Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Yuyu Pharma Plans to Enter the U.S. and European Markets for Hair Loss Treatment

Details:

Dutasteride inhibits both Type I and Type II 5-alpha reductase which act to transform testosterone, a male hormone, into a DHT hormone. In scientific studies, excess DHT is understood to be the cause of hair loss.

Lead Product(s): Dutasteride

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 29, 2022

ASK
US

Upload
your Pipeline Activity

Yuyu Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Yuyu Pharma Attendance at European Pharmaceutical Conference

Details:

Preclinical data show that YP-P10 was a more active immunomodulator than lifitegrast in lowering pro-inflammatory cytokines and chemokines production in human peripheral blood mononuclear cells (PBMCs) when stimulated by lipopolysaccharide (LPS)

Lead Product(s): YP-P10

Therapeutic Area: Ophthalmology Product Name: YP-P10

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2022

ASK
US

Upload
your Pipeline Activity

Yuyu Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution for the Treatment of Dry Eye Disease

Details:

YP-P10, opthalmic solution, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties to treat patients with dry eye disease (DED).

Lead Product(s): YP-P10

Therapeutic Area: Ophthalmology Product Name: YP-P10

Highest Development Status: Phase II Product Type: Peptide

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY